Method and apparatus for detection of acid reflux

• US 6,475,145 B1
• Filed: 05/17/2000
• Issued: 11/05/2002
• Est. Priority Date: 05/17/2000
• Status: Expired due to Fees

• Current Assignee: Esophamet Corp.
• Original Assignee: Baymar, Inc.
• Inventors: Baylor, Richard A.
• Primary Examiner(s): WINAKUR, ERIC FRANK
• Application Number:
  US09/573,136
• Time in Patent Office: 902 Days
• Field of Search: 600/309, 600/364, 600/348, 600/350, 600/361
• US Class Current: 600/309
• CPC Class Codes: A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissuemeasuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06
• CPC Class Codes: A61B 5/14539 for measuring pH
• CPC Class Codes: A61B 5/4211 Diagnosing or evaluating reflux
• CPC Class Codes: A61B 5/4233 oesophagus

Abstract

Methods and apparatus for monitoring gastrointestinal pH levels are disclosed. A gastroesophageal diagnostic device for determining the duration of exposure of a patient'"'"'s esophagus to pH levels clinically significant for gastroesophageal reflux disease is disclosed.

Claims

1. A device for determining the duration of exposure of a patient'"'"'s esophagus to pH levels clinically significant for gastroesophageal reflux disease comprising:

a capsule containing a known amount of radioactive material, and being subject to pH-dependent degradation at pH less than about pH 4, and being of a size to be readily swallowable;

a cord, the cord having a proximal end and a distal end, the proximal end being connected to the capsule, whereby the cord allows positioning and retrieval of the capsule.

2. A device according to claim 1 further comprising an attachment member, the attachment member being connected to the distal end of the cord, whereby the attachment member allows the distal end of the cord to be fixed in a selected position.

3. A device according to claim 1 further comprising a weight, the weight being positioned on the cord and adjacent to the capsule.

4. A device according to claim 1 wherein the cord includes measuring indicia along the length of the cord, whereby the measuring indicia allow measurement of the length of cord inserted into a patient.

5. A device according to claim 1 wherein the capsule further comprises a polymer.

6. A device according to claim 1 wherein the amount of radioactive material present in the capsule is about 3 micro-Curies to about 4 micro-Curies.

7. A device according to claim 1 wherein the amount of radioactive material present in the capsule is less than about 3 micro-Curies.

8. A device according to claim 1 wherein the amount of radioactive material present in the capsule is greater than about 4 micro-Curies.

9. A device according to claim 1 wherein the radioactive material is selected from the group consisting of Gallium-67, Molybdenum-99, Indium-111, and Thallium-201.

10. A device according to claim 9 wherein the amount of radioactive material present in the capsule is about 3 micro-Curies to about 4 micro-Curies.

11. A method of detecting gastroesophageal reflux comprising:

providing a gastroesophageal diagnostic device, said gastroesophageal diagnostic device comprising a capsule having a cord attached thereto, the capsule containing a known first level of radioactivity and being subject to pH-dependent degradation at pH levels less than about pH 4;

introducing the gastroesophageal diagnostic device into the esophagus of a patient;

positioning the gastroesophageal diagnostic device in the esophagus of the patient such that the capsule is positioned in the lower one-third of the esophagus;

leaving the gastroesophageal diagnostic device in the esophagus of the patient for a selected time, whereby the capsule degrades and looses radioactivity in a pH-dependent manner;

removing the gastroesophageal diagnostic device from the patient after the selected time;

determining a second level of radioactivity remaining in the capsule after the selected time,

calculating the reduction in the amount of radioactivity from the first level of radioactivity in the capsule to the second level of radioactivity in the capsule; and

determining the percentage of the selected time during which the capsule was exposed to pH levels less than about pH 4, wherein the reduction in the amount of radioactivity is correlated to the percentage of the selected time during which the capsule was exposed to pH levels less than about pH 4, and wherein exposure of the capsule to pH levels less than about pH 4 for at least a determined percent of the selected time is indicative of gastroesophageal reflux disease.

12. The method of claim 11 wherein the determined percent of the selected time is at least about five percent.

13. The method of claim 11 wherein the determined percent of the selected time is at least about ten percent.

14. The method of claim 11 wherein the determined percent of the selected time is at least about fifteen percent.

15. The method of claim 11 wherein the determined percent of the selected time is greater than about fifteen percent.

16. The method of claim 11 wherein the selected time for leaving the gastroesophageal diagnostic device in the esophagus of the patient is about 24 hours.

17. The method of claim 11 wherein the selected time for leaving the gastroesophageal diagnostic device in the esophagus of the patient is less than 24 hours.

18. A method of determining the duration of exposure of a patient'"'"'s gastrointestinal tract to pH levels less than about pH 4 comprising:

providing a gastrointestinal diagnostic device, said gastrointestinal diagnostic device comprising a capsule having a cord attached thereto, the capsule containing a known first level of radioactivity and being subject to pH-dependent degradation at pH levels less than about pH 4;

introducing the gastrointestinal diagnostic device into the gastrointestinal tract of a patient;

positioning the gastrointestinal tract of a patient device in the gastrointestinal tract of the patient such that the capsule is positioned at a predetermined location in gastrointestinal tract of the patient;

leaving the gastrointestinal diagnostic device in the gastrointestinal tract of the patient for a selected time, whereby the capsule degrades and looses radioactivity in a pH-dependent manner;

removing the gastrointestinal diagnostic device from the patient after the selected time;

determining a second level of radioactivity remaining in the capsule after the selected time;

calculating the reduction in the amount of radioactivity from the first level of radioactivity in the capsule to the second level of radioactivity in the capsule; and

determining the percentage of the selected time during which the capsule was exposed to pH levels less than about pH 4, wherein the reduction in the amount of radioactivity is correlated to the percentage of the selected time during which the capsule was exposed to pH levels less than about pH 4.